Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
VISTIN PHARMA Aktie jetzt für 0€ handeln | |||||
15.04. | Vistin Pharma ASA: Invitation to Q1 2025 conference call | 1 | Oslo Børs | ||
13.02. | Vistin Pharma ASA: Key information relating to the proposed cash dividend | 1 | GlobeNewswire (USA) | ||
13.02. | Vistin Pharma ASA: Fourth quarter and preliminary 2024 financial results | 95 | GlobeNewswire (Europe) | Oslo, Norway, 13th of February 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the fourth quarter and preliminary results of 2024. Revenue in the fourth quarter ended at MNOK... ► Artikel lesen | |
06.02. | Vistin Pharma ASA: Invitation to Q4 2024 conference call | 1 | Oslo Børs | ||
16.12.24 | Vistin Pharma ASA: Financial calendar | 1 | Oslo Børs | ||
06.11.24 | Vistin Pharma ASA: Ex dividend NOK 0.50 today | 1 | GlobeNewswire (USA) | ||
05.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 05.11.2024 | 462 | Xetra Newsboard | Das Instrument W28 CA2987641016 EUR.ENERGY METALS CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 05.11.2024 und ex Kapitalmassnahme am 06.11.2024 The instrument W28 CA2987641016 EUR.ENERGY METALS... ► Artikel lesen | |
31.10.24 | Vistin Pharma ASA: Third quarter and YTD 2024 financial results | 131 | GlobeNewswire (Europe) | Oslo, Norway, 31st of October 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2024. Revenue in the third quarter ended at MNOK 106 compared to MNOK... ► Artikel lesen | |
24.10.24 | Vistin Pharma ASA: Invitation to Q3 2024 conference call | 4 | Oslo Børs | ||
23.08.24 | Vistin Pharma ASA: Second quarter and first half 2024 financial results | 178 | GlobeNewswire (Europe) | Oslo, Norway, 23rd of August 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2024. Revenue in the second quarter ended at MNOK 106 compared to MNOK... ► Artikel lesen | |
05.06.24 | Dividendenbekanntmachungen (05.06.2024) | 15.228 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 2G ENERGY AG DE000A0HL8N9 - 0,17 EUR ACCOR SA FR0000120404 - 1,18 EUR ACCOR SA ADR US00435F3091 0,2526 USD 0,2322 EUR ADESSO SE DE000A0Z23Q5 - 0... ► Artikel lesen | |
23.05.24 | Vistin Pharma ASA: Minutes from the annual general meeting 2024 | 187 | GlobeNewswire (Europe) | Oslo, Norway, 23 May 2024 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 23 May 2024. All matters were resolved as proposed in... ► Artikel lesen | |
24.04.24 | Vistin Pharma ASA: First quarter 2024 financial results | 172 | GlobeNewswire (Europe) | Oslo, Norway, 24th of April 2024 Vistin Pharma ASA (VISTN) today announces the financial results for the first quarter of 2024. Revenue in the first quarter ended at MNOK 104 compared to MNOK... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PHOTOCURE | 4,415 | +0,68 % | Photocure appoints Jane Healy as Vice President and General Manager EMEA | OSLO, Norway, March 26, 2025 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced the appointment of Jane Healy as Vice President and General Manager EMEA.
Ms.... ► Artikel lesen | |
ARCTICZYMES TECHNOLOGIES | 1,380 | +0,73 % | ArcticZymes Technologies ASA: ArcticZymes Technologies announces Q4 2024 Financial results | ||
ZELLUNA | 1,006 | +1,00 % | Trading halt in Zelluna ASA | The Exchange has decided to halt the trading in shares of Zelluna ASA (ZLNAo, ISIN Code NO0013524942, orderbook ID 174696) as the shares have been halted on Oslo Stock Exchange.
For further information... ► Artikel lesen | |
AQUA BIO TECHNOLOGY | 0,049 | +0,82 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 13.03.2025 | Das Instrument A1D0 CA13640F2044 CANADIAN NEXUS TEAM NEW EQUITY wird cum Kapitalmassnahme gehandelt am 13.03.2025 und ex Kapitalmassnahme am 14.03.2025 The instrument A1D0 CA13640F2044 CANADIAN NEXUS... ► Artikel lesen | |
NAVAMEDIC | 1,600 | +1,27 % | Navamedic ASA: Navamedic Q4 and Full Year 2024: Continued growth in a year with investments in new growth initiatives | OSLO, Norway, Feb. 12, 2025 /PRNewswire/ -- For the full year 2024, Navamedic ASA (OSE: NAVA), a Nordic pharma company and reliable provider of high-quality products to hospitals and pharmacies... ► Artikel lesen | |
METSERA | 19,510 | 0,00 % | Why did Lilly data for oral GLP-1 boost Structure and Metsera? | ||
HARROW | 23,240 | -3,13 % | Harrow Health Aktie: Ein dunkler Schatten fällt! | Das Pharmaunternehmen verbucht starke Quartalszahlen mit 66,83 Millionen Dollar Umsatz, während die Aktie dennoch einen Abwärtstrend von 5,75% fortsetzt. Der Aktienkurs von Harrow Health ist am Freitag... ► Artikel lesen | |
UNIVERSE PHARMACEUTICALS | 4,250 | 0,00 % | Universe Pharmaceuticals Plans To Effect Share Consolidation | BEIJING (dpa-AFX) - Universe Pharmaceuticals (UPC) said it plans to effect a share consolidation of 40 ordinary shares with par value of $0.28125 per share each in the companys issued
and... ► Artikel lesen | |
ZHENGYE BIOTECHNOLOGY | 7,920 | 0,00 % | Zhengye Biotechnology Holding Limited Announces Closing of Initial Public Offering | Jilin, China, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development... ► Artikel lesen | |
ASTRIA THERAPEUTICS | 4,110 | +1,73 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
ETON PHARMACEUTICALS | 14,260 | -0,56 % | Eton Pharmaceuticals Out-Licenses International Rights to Increlex | DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
SUNSHINE BIOPHARMA | 1,290 | 0,00 % | Sunshine Biopharma Inc.: Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion | FORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas... ► Artikel lesen | |
AQUESTIVE THERAPEUTICS | 2,585 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
CHINA SXT PHARMACEUTICALS | 1,010 | 0,00 % | China SXT Pharmaceuticals Stock Surges 90% | ||
SHINECO | 0,509 | 0,00 % | Shineco, Inc.: Shineco Announces Acquisition of Medical Device Company | The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"... ► Artikel lesen |